---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046513"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T03:09:15.272481+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Delcath Q3 revenue $11.2M (+44% QoQ); HEPZATO adoption grows; debt-free after warrant exercise

## Summary
- Q3 total revenue $11.2M (vs $0.4M prior year); HEPZATO $10.0M, CHEMOSAT $1.2M.
- Activated 12 HEPZATO treatment centers in U.S.; additional centers in training pipeline.
- Ended Q3 with $14.0M cash; quarterly cash burn $3.6M.
- Post-Q3: paid $2.8M final Rosalind note; ~$25M from Tranche B warrant exercise; no debt.
- Advancing HEPZATO programs for liver-dominant colorectal and breast cancers.

## SEC filing metadata
- accession: 0001628280-24-046513
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828024046513/0001628280-24-046513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828024046513/dcth-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046513
- JSON: https://secwatch.observer/filing/0001628280-24-046513.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.